Xin-Bao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xin-Bao Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Yan Li
Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China
29 shared publications - Yu-Lin Lin
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
29 shared publications - Ru Ma
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
28 shared publications - He-Liang Wu
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
27 shared publications - Hong-Bin Xu
Department of Myxoma, Aerospace Center Hospital, Beijing, China
27 shared publications - Jun-Qi Zhu
Thorgene Co., Ltd, Beijing, China
27 shared publications
Latest Publications
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The clinicopathological characteristics of 49 PMP
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The clinicopathological characteristics of 49 PMP
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The cophenetic coefficient for selecting optimal NMF rank.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The cophenetic coefficient for selecting optimal NMF rank.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Pseudomyxoma peritonei (PMP) is a rare malignant clinical syndrome with little known about the global mutation profile. In this study, whole-exome sequencing (WES) was performed in 49 appendiceal PMP to investigate mutation profiles and mutation signatures. A total of 4,020 somatic mutations were detected, with a median mutation number of 56 (1–402). Tumor mutation burden (TMB) was generally low (median 1.55 mutations/Mb, 0.12–11.26 mutations/Mb). Mutations were mainly enriched in the function of cancer-related axonogenesis, extracellular matrix–related processes, calcium signaling pathway, and cAMP signaling pathway. Mutations in FCGBP, RBFOX1, SPEG, RTK-RAS, PI3K-AKT, and focal adhesion pathways were associated with high-grade mucinous carcinoma peritonei. These findings revealed distinct mutation profile in appendiceal PMP. Ten mutation signatures were identified, dividing patients into mutation signature cluster (MSC) 1 (N = 28, 57.1%) and MSC 2 (N = 21, 42.9%) groups. MSC (P = 0.007) was one of the four independent factors associated with 3-year survival. TMB (P = 0.003) and microsatellite instability (P = 0.002) were independent factors associated with MSC 2 grouping. Taken together, our findings provided a broader view in the understanding of molecular pathologic mechanism in appendiceal PMP and may be critical to developing an individualized approach to appendiceal PMP treatment.Implications:This work describes exhaustive mutation profile of PMP based on WES data and derives ten mutation signatures, which divides patients into two clusters and serve as an independent prognostic factor associated with 3-year survival.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Pseudomyxoma peritonei (PMP) is a rare malignant clinical syndrome with little known about the global mutation profile. In this study, whole-exome sequencing (WES) was performed in 49 appendiceal PMP to investigate mutation profiles and mutation signatures. A total of 4,020 somatic mutations were detected, with a median mutation number of 56 (1–402). Tumor mutation burden (TMB) was generally low (median 1.55 mutations/Mb, 0.12–11.26 mutations/Mb). Mutations were mainly enriched in the function of cancer-related axonogenesis, extracellular matrix–related processes, calcium signaling pathway, and cAMP signaling pathway. Mutations in FCGBP, RBFOX1, SPEG, RTK-RAS, PI3K-AKT, and focal adhesion pathways were associated with high-grade mucinous carcinoma peritonei. These findings revealed distinct mutation profile in appendiceal PMP. Ten mutation signatures were identified, dividing patients into mutation signature cluster (MSC) 1 (N = 28, 57.1%) and MSC 2 (N = 21, 42.9%) groups. MSC (P = 0.007) was one of the four independent factors associated with 3-year survival. TMB (P = 0.003) and microsatellite instability (P = 0.002) were independent factors associated with MSC 2 grouping. Taken together, our findings provided a broader view in the understanding of molecular pathologic mechanism in appendiceal PMP and may be critical to developing an individualized approach to appendiceal PMP treatment.Implications:This work describes exhaustive mutation profile of PMP based on WES data and derives ten mutation signatures, which divides patients into two clusters and serve as an independent prognostic factor associated with 3-year survival.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Flow-chart of sample processing and subsequent analyses.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Flow-chart of sample processing and subsequent analyses.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The correlation between clinicopathological factors and two MSC groups
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The correlation between clinicopathological factors and two MSC groups
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The correlation between clinicopathological factors and two MSC groups
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The correlation between clinicopathological factors and two MSC groups
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The sensitivity and specificity of the binary logistic model
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The sensitivity and specificity of the binary logistic model
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The cophenetic coefficient for selecting optimal NMF rank.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
The cophenetic coefficient for selecting optimal NMF rank.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Flow-chart of sample processing and subsequent analyses.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Flow-chart of sample processing and subsequent analyses.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Comparison between S1 – S10 signatures in our study and 30 signatures in COSMIC database.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Comparison between S1 – S10 signatures in our study and 30 signatures in COSMIC database.